从去年以来，一些疫苗价格战愈演愈烈，已引发业界担忧。 在上述倡议出台的背后，从去年以来，在公费市场，一些疫苗价格持续下探。 比如今年9月，在2025年北京流感疫苗免疫类和非免疫类招标采购项目中，上海生物制品研究所的三价 流感疫苗中标价5.5元/支，再度创下公费流感疫苗市场的价格新低。 11月19日下午，引导行业持续健康发展，中国疫苗行业协会发布了《关于反对"内卷式"竞争促进疫苗及 其相关生物制品行业高质量发展的倡议》，旨在助力行业打破"内卷"，构建健康有序的良性生态。 该倡议提出，中国疫苗行业协会全体会员须严格遵循《中华人民共和国疫苗管理法》《中华人民共和国 价格法》，严格遵守行业自律公约，坚持公平、合法、诚实信用原则，以生产经营成本与市场供求状况 为定价基本依据，依法自主合理定价，自觉维护市场价格稳定，共同营造公平有序的竞争环境。坚决抵 制无序低价竞争，在招投标全流程中，严禁以低于成本的报价参与竞标，切实保障产品与服务的质量标 准。 中国疫苗行业协会是在国家工信部、药监局、卫健委、国资委、民政部等5部委领导和指导下，以原中 国医药企业发展促进会为基础，由疫苗及其相关生物制品行业的企事业单位、社会团体和个人自 ...

Key Points - 合富中国's stock will resume trading on November 20 after completing an investigation into unusual trading fluctuations, confirming normal business operations and no undisclosed significant matters [1] - 中金公司 plans to merge with 东兴证券 and 信达证券, leading to a suspension of its A-shares starting November 20 due to uncertainties surrounding the merger [1] - 大为股份 is progressing with the transition from exploration to mining rights for its lithium battery project in Hunan, having received necessary approvals [1] - 燕东微's major shareholders plan to reduce their stakes by up to 2.5% through block trades or centralized bidding from December 11, 2025, to March 11, 2026 [2] - 中水渔业's major shareholder reduced its stake to 5% after selling 258.88 million shares [3] - 韵达股份 reported a slight decline in express service revenue for October 2025, totaling 4.495 billion yuan, a year-on-year decrease of 0.88% [4] - 倍杰特 intends to acquire a 55% stake in 大豪矿业 for 224.8 million yuan [4] - 辰奕智能 plans to acquire a 55% stake in 华泽电子 through cash [4] - 赣粤高速's actual controller will change from the provincial transportation department to the provincial state-owned assets supervision and administration commission [5] - 东软集团 received a notification for a 4.2 billion yuan contract for intelligent cockpit controllers from a major domestic automotive manufacturer [5] - 海正药业's subsidiary plans to invest in a pet prescription food project [5] - 龙利得's controlling shareholder plans to increase its stake by at least 56 million yuan [6] - 新兴装备's shareholders plan to reduce their stakes by up to 3.13% [6] - 普洛药业 plans to repurchase shares worth between 180 million and 360 million yuan [6]

【导读】中国疫苗行业协会：严禁以低于成本的报价参与竞标 中国基金报记者 卢鸰 倡议提出，中国疫苗行业协会全体会员须严格遵循《中华人民共和国疫苗管理法》《中华人民共和国价格法》，以生产经营成本与市场供求状况为定价基 本依据，依法自主合理定价，自觉维护市场价格稳定，共同营造公平有序的竞争环境。坚决抵制无序低价竞争，在招投标全流程中，严禁以低于成本的报 价参与竞标，切实保障产品与服务的质量标准。 受此影响，智飞生物、沃森生物等疫苗上市公司的盈利持续大幅下滑，其股价也持续暴跌。 智飞生物(300122) < G 闭市 11-19 15:30:54 通 融 20.84 额 3.05亿 股本23.94亿 市盈 -37.3 万得 盘口 -0.20 -0.95% 换 1.03% 市值 499亿 市净 1.70 分时 五日 日K 周K 月K 更多 [0] 叠加 设均线 MA 5:21.76↑ 10:21.57↓ 20:24.96↓ 前复权 159.98 <146.21 83.83 2019-02 2021-05 2023-08 2025-11 016-11 - 编辑：杜妍 倡议要求，全体会员应坚持创新驱动发展，推动关键核心技术 ...

Mergers and Acquisitions - Chenyi Intelligent plans to acquire 55% of Huaze Electronics through cash payment [1] - Beijiete's wholly-owned subsidiary intends to acquire 55% of Dahao Mining for 225 million yuan [1] Share Buybacks and Equity Transfers - Chenzhan Optoelectronics' controlling shareholder is transferring 5.02% of shares [2] - Huamin Co., Ltd. plans to transfer 5.17% of shares by Jianxianghuihong [2] - Pro Pharmaceutical intends to repurchase shares worth between 180 million to 360 million yuan, with a maximum price of 23 yuan per share [2] - Ganyue Expressway's actual controller will change from the Provincial Department of Transportation to the Provincial State-owned Assets Supervision and Administration Commission [2] External Investments and Daily Operations - Hefei China has completed its suspension review and resumed trading [3] - Dwei Co., Ltd. is advancing the procedures for lithium battery new energy projects in Hunan Chenzhou [4] - Desay SV plans to launch an AI computing terminal for the robotics sector [4] - Neusoft Group received a notification from a major domestic automotive manufacturer to supply intelligent cockpit domain controllers, with a total expected supply amount of 4.2 billion yuan [4] - Junyi Digital plans to invest 120 million yuan in Guanghong Precision, acquiring 60% ownership post-investment [5] - Dongfang Electric intends to invest 910 million yuan to hold 49% in a joint venture [6] - Bailian Group's subsidiary plans to transfer 100% of its stake in Yangpu Century Bailian for 78.286 million yuan [6] - Ruisheng Intelligent's subsidiary won a bid for a China Mobile ICT project, focusing on computing server hardware and systems [6] - Zhifei Biological's clinical trial application for the ZFA01 adjuvant vaccine has been accepted [7] - Haizheng Pharmaceutical's subsidiary is collaborating with East China Institute on a biomanufacturing project for heparin [8] - Baiyang Pharmaceutical's Zap Therapeutic plans to invest 4.9 million USD in Baiyang Sap to expedite the clinical introduction of the ZAP-X Mars surgical robot [8] - Jinbei Automotive plans to invest 5.8 billion yuan and purchase equity in Changchun Zhongtuo Molding Technology [9] - Baili Tianheng has secured a commitment from Bank of China Sichuan Branch for a total of no less than 8 billion yuan in comprehensive credit support [10]

智飞生物表示，公司的重组带状疱疹ZFA01佐剂疫苗(CHO细胞)采用自主研制的新型佐剂，可同时激发 细胞免疫与体液免疫反应，免疫应答更为全面，有望增强疫苗的保护效果。该疫苗临床试验申请获得受 理，是公司新型佐剂技术平台应用，聚焦创新技术、增强核心攻关的成果。若本项目进展顺利，将进一 步丰富公司成人疫苗品种，完善公司产品布局，强化公司的市场地位。 北京商报讯(记者丁宁)11月19日晚间，智飞生物（300122）发布公告称，公司于近日获悉，由全资子公 司安徽智飞龙科马生物制药有限公司(以下简称"智飞龙科马")研发的重组带状疱疹ZFA01佐剂疫苗(CHO 细胞)获得国家药品监督管理局药物临床试验申请受理通知书。自受理之日起60日内，未收到药审中心 否定或质疑意见的，智飞龙科马可以按照提交的方案开展临床试验。 ...

北京商报讯（记者 王寅浩 宋雨盈）11月19日，智飞生物发布公告称，公司全资子公司安徽智飞龙科马 生物制药有限公司（以下简称"智飞龙科马"）研发的重组带状疱疹ZFA01佐剂疫苗（CHO细胞）获得国 家药品监督管理局药物临床试验申请受理通知书。根据公告，自受理之日起60日内，未收到药审中心否 定或质疑意见的，智飞龙科马可以按照提交的方案开展临床试验。 ...

格隆汇11月19日｜智飞生物公告，近日获悉，由全资子公司安徽智飞龙科马生物制药有限公司研发的重 组带状疱疹ZFA01佐剂疫苗（CHO细胞）获得国家药品监督管理局药物临床试验申请受理通知书（受理 号：CXSL2500978）。自受理之日起60日内，未收到药审中心否定或质疑意见的，智飞龙科马可以按 照提交的方案开展临床试验。 ...

每经AI快讯，11月19日，智飞生物（300122）(300122.SZ)公告称，公司全资子公司智飞龙科马研发的 重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得国家药品监督管理局药物临床试验申请受理通知书。该疫 苗采用自主研制的新型佐剂，可同时激发细胞免疫与体液免疫反应，有望增强疫苗的保护效果。智飞龙 科马研发的重组带状疱疹ZFA01佐剂疫苗(CHO细胞)用于预防由带状疱疹感染引起的疾病。 ...

人民财讯11月19日电，智飞生物（300122）11月19日公告，全资子公司智飞龙科马研发的重组带状疱疹 ZFA01佐剂疫苗(CHO细胞)获得国家药品监督管理局药物临床试验申请受理通知书。 ...

智飞生物（300122）(300122.SZ)公告，公司全资子公司安徽智飞龙科马生物制药有限公司(简称"智飞龙 科马")研发的重组带状疱疹ZFA01佐剂疫苗(CHO细胞)获得国家药品监督管理局药物临床试验申请受理 通知书。自受理之日起60日内，未收到药审中心否定或质疑意见的，智飞龙科马可以按照提交的方案开 展临床试验。 ...